LISA KAHLMAN — Lobbyist Profile | Poliscope

LISA KAHLMAN

Filings

Clients

Firms

Years active

2024–2026

Associated filing income

—

How to read the money

Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.

Clients represented

Client	Filings	Years
ULTRAGENYX PHARMACEUTICAL INC.	11	2024–2026

Lobbying firms

Firm	Filings	Years
ULTRAGENYX PHARMACEUTICAL INC.	11	2024–2026

Original LDA source filings (11)

Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.

ULTRAGENYX PHARMACEUTICAL INC. via ULTRAGENYX PHARMACEUTICAL INC.

2026 · third_quarter · Q3

Firm income: —Client expense: $280,000Open original LDA filing ↗

Assigned issues and filing targets (3 issues)

BUD

Budget/Appropriations

Issues related to drug development, access and reimbursement for rare and ultra rare diseases.

MMM

Medicare/Medicaid

Issues related to drug development, access and reimbursement for rare and ultra rare diseases.

HCR

Source: Senate LDA

Show 7 more original filings

ULTRAGENYX PHARMACEUTICAL INC. via ULTRAGENYX PHARMACEUTICAL INC.

2025 · third_quarter · Q3

Firm income: —Client expense: $140,000Open original LDA filing ↗

Assigned issues and filing targets (3 issues)

HCR

Health Issues

Issues related to drug development, access and reimbursement for rare and ultra rare diseases.

BUD

Budget/Appropriations

Issues related to drug development, access and reimbursement for rare and ultra rare diseases.

MMM

Medicare/Medicaid

Issues related to drug development, access and reimbursement for rare and ultra rare diseases.

Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE

ULTRAGENYX PHARMACEUTICAL INC. via ULTRAGENYX PHARMACEUTICAL INC.

2025 · first_quarter · Q1

Firm income: —Client expense: $330,000Open original LDA filing ↗

Assigned issues and filing targets (3 issues)

HCR

Health Issues

Issues related to drug development, access and reimbursement for rare and ultra rare diseases.

BUD

Budget/Appropriations

Issues related to drug development, access and reimbursement for rare and ultra rare diseases.

MMM

Medicare/Medicaid

Issues related to drug development, access and reimbursement for rare and ultra rare diseases.

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

ULTRAGENYX PHARMACEUTICAL INC. via ULTRAGENYX PHARMACEUTICAL INC.

2024 · fourth_quarter · Q4

Firm income: —Client expense: $110,000Open original LDA filing ↗

Assigned issues and filing targets (3 issues)

HCR

Health Issues

Issues related to drug development, access and reimbursement for rare and ultra rare diseases.

MMM

Medicare/Medicaid

Issues related to drug development, access and reimbursement for rare and ultra rare diseases.

BUD

Budget/Appropriations

Issues related to drug development, access and reimbursement for rare and ultra rare diseases.

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

ULTRAGENYX PHARMACEUTICAL INC. via ULTRAGENYX PHARMACEUTICAL INC.

2024 · third_quarter · Q3

Firm income: —Client expense: $80,000Open original LDA filing ↗

Assigned issues and filing targets (3 issues)

HCR

Health Issues

Issues related to drug development, access and reimbursement for rare and ultra rare diseases.

BUD

Budget/Appropriations

Issues related to drug development, access and reimbursement for rare and ultra rare diseases.

MMM

Medicare/Medicaid

Issues related to drug development, access and reimbursement for rare and ultra rare diseases.

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

ULTRAGENYX PHARMACEUTICAL INC. via ULTRAGENYX PHARMACEUTICAL INC.

2024 · second_quarter · Q2

Firm income: —Client expense: $30,000Open original LDA filing ↗

Assigned issues and filing targets (3 issues)

BUD

Budget/Appropriations

Issues related to drug development, access and reimbursement for rare and ultra rare diseases.

HCR

Health Issues

Issues related to drug development, access and reimbursement for rare and ultra rare diseases.

MMM

Medicare/Medicaid

Issues related to drug development, access and reimbursement for rare and ultra rare diseases.

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

ULTRAGENYX PHARMACEUTICAL INC. via ULTRAGENYX PHARMACEUTICAL INC.

2024 · first_quarter · Q1

Firm income: —Client expense: $220,000Open original LDA filing ↗

Assigned issues and filing targets (3 issues)

BUD

Budget/Appropriations

Issues related to drug development, access and reimbursement for rare and ultra rare diseases.

HCR

Health Issues

Issues related to drug development, access and reimbursement for rare and ultra rare diseases.

MMM

Medicare/Medicaid

Issues related to drug development, access and reimbursement for rare and ultra rare diseases.

Filing targets: HOUSE OF REPRESENTATIVES

ULTRAGENYX PHARMACEUTICAL INC. via ULTRAGENYX PHARMACEUTICAL INC.

2024 · first_quarter · RR

Firm income: —Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (3 issues)

BUD

Budget/Appropriations

Issues related to drug development, access and reimbursement for rare and ultrarare diseases.

MMM

Medicare/Medicaid

Issues related to drug development, access and reimbursement for rare and ultrarare diseases.

HCR

Health Issues

Issues related to drug development, access and reimbursement for rare and ultrarare diseases.